Skip to main content

10-24-2017 | Pioglitazone | News

News in brief

Patients treated with pioglitazone may have reduced gout risk

medwireNews: Observational findings suggest that pioglitazone use may be associated with a reduced risk for gout among patients with diabetes.

“The prevention of gout in diabetic populations is important” given that the incidence of gout is higher among patients with diabetes than the general population, explain Hugo You-Hsien Lin (Kaohsiung Medical University, Taiwan) and study co-authors.

Using data from the Taiwanese National Health Insurance program, the team found that 8.2% of 30,100 diabetes patients who were treated with pioglitazone developed gout over an average 4.48 years of follow-up, compared with 9.9% of 90,300 participants who were not treated with the drug.

This was equivalent to a significant 19% reduced risk for gout with pioglitazone treatment after adjustment for age, sex, comorbidities, and medications, and a dose-dependent association was observed, report the researchers in Rheumatology.

“Additional epidemiological studies and biological mechanisms are required to clarify the associations among pioglitazone, [insulin resistance] and gout,” they conclude.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group

Related topics

CME-accredited GLP-1RAs webcast

Learn more about GLP-1RAs with John Wilding, Julie Lovshin and Kamlesh Khunti

CME-accredited GLP-1RAs webcast on real-world data

Led by Melanie Davies, Stewart Harris & Takashi Kadowaki, this on-demand webcast focuses on treatment with GLP-1RAs, based on real-world data, and the emerging landscape of GLP-1RAs in the context of approved guidelines.

Image Credits